Home Page

All news, publications, and updates from Seek Labs.

Diagnostics, Featured, Home Page, News

May 7, 2026

Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing

Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing Newly issued patent covers foundational amplification chemistry designed to support sensitive molecular detection without thermal cycling or centralized laboratory infrastructure May 7, 2026 SALT LAKE CITY, UT (Business Wire) — Seek Labs, a private TechBio company building programmable platforms to decode,…
Corporate, Featured, Home Page, News

March 19, 2026

Seek Labs Joins BioMaP-Consortium to Support U.S. Biomanufacturing Preparedness Efforts

Seek Labs Joins BioMaP-Consortium to Support U.S. Biomanufacturing Preparedness Efforts As a member of the BioMaP-Consortium, Seek Labs gains access to a collaborative network advancing next-generation biomanufacturing and healthcare innovation. March 19, 2026 Seek Labs today announced that it has joined the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a national public-private partnership focused on strengthening the…
Featured, Home Page, News, Therapeutics

February 17, 2026

Seek Labs Awarded $2M USDA Grant for CRISPR Avian Flu Therapeutic

Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat Avian Flu in Partnership with Canadian Food Inspection Agency USDA grant is part of a broader federal push to find innovative solutions to fight the highly infectious avian flu (HPAI), which continues to spread globally and impact egg and poultry…
Home Page, Papers

December 8, 2025

Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats

Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats December 8, 2025 Read the full open-access review in Viruses Seek Labs today announced the publication of a new editorial review in Viruses (MDPI), authored by Alison O’Mahony, Senior VP of Research, and Douglas P. Gladue, VP…
Home Page, News, Therapeutics

December 5, 2025

CRISPR Treatments for AI-Designed Synthetic Viruses: Rapid Programmable Countermeasures for Emerging and Engineered Viruses
Blog, Featured, Home Page, News

October 23, 2025

Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation

Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation At Seek Labs, every day is World CRISPR Day. Our work in programmable therapeutics builds upon the same principles that make CRISPR so revolutionary: precision, adaptability, and speed. As we reflect on this transformative technology, we’re not just looking at…

Stay connected

Follow the work as it unfolds.

Stay connected to company milestones, scientific insights, and the work unfolding across BioSeeker, SAT, and Seek Diagnostics.

Home Page

Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing

Seek Labs Joins BioMaP-Consortium to Support U.S. Biomanufacturing Preparedness Efforts

Seek Labs Awarded $2M USDA Grant for CRISPR Avian Flu Therapeutic

Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats

CRISPR Treatments for AI-Designed Synthetic Viruses: Rapid Programmable Countermeasures for Emerging and Engineered Viruses

Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation

Follow the work as it unfolds.